中国 生物制药研发和产品周 - s3-ap-southeast-1 ...
IBC LIFE SCIENCES
15 - 17 Hilton China
May 2018 Shanghai Hongqiao
SEE
Hotel,
REGISTRRAAATTTIETOSRN AAPAVCGATEIIVLFOAERBGDLREETO!AUILPS!
UNRIVALLED LINE-UP OF BIOPHARMA LEADERS
Zhihao (Peter) Qiu Branch Chief, Division of Inspectional Assessment Office of Process and Facilities, Office of Pharmaceutical Quality
CDER, FDA, U.S.
Andrew Huntley Senior Managing Director
BDA Partners, UK
Jerry Yang
Dong Huifang
SVP, Process & Product
Director of Cell Line Development
Development, Hangzhou JUST
WuXi Biologics, China
Biotherapeutics Co., Ltd., China
Xu Wei Vice President Manufacturing
Innovent Biologics, China
Bryan Kim Vice President of Business
Development Samsung Bioepis, Korea
Dr. Dennis Yu Xia Vice President of Manufacturing
and Quality Akeso Bio, China
Jiang Junjun Assistant Director WuXi Biologics, China
Minseob Lee Team Leader of R&D CMC/PM
Celltrion R&D, Korea
Yun Kang Vice President of Manufacturing
Generon Beijing, China
Yifang Wu President Wanbang Biopharmaceuticals Co., Ltd, China
Jian Dong Vice President & Site Head of
Manufacturing Wuxi AppTec, China
Dr. Jinyou Zhang Senior Vice President/Head, Bio Development and Manufacturing
BeiGene Co Ltd, China
Sunny Zhou Professor, Department of Chemistry and Chemical Biology Northeastern University, USA
Alvin Luk Senior Vice President and Chief Medical Officer ? Global Clinical
Operations and Affairs Shanghai Henlius Biotech Co
Ltd, China
Shaoqing Yang Vice President
Zhejiang Doer Biologics Co., China
Zack Zheng, Ph.D. VP of Process Development
(Wuhan) JHL BioTech, China
Prof. David James University of Sheffield, UK
Dr Jun Yuan Vice President Quacell Biotech, China
Dr. Jacqueline Ming Liu Vice President
TOT Biopharma, China
Prof. Dr. Florian Turk Head Global Payor Marketing,
Sales and Relations Sandoz Biopharmaceuticals Sandoz International GmbH,
Germany
Dr Xin Zhang Vice President of Global Clinical
Operations and Affairs Shanghai Henlius Biotech, Inc.,
China
Sam Zhang Senior Principal Scientist/Group Leader, Cell Line Development,
Bioprocess R&D Pfizer Inc, USA
Dr Qiwei Wu, Ph.D Vice President of Process Development and Manufacturing Livzon Mabpharma, China
Ng Say Kong Staff Scientist, Animal Cell Technology 2, Bioprocessing
Technology Institute A*STAR, Singapore
CHINA'S LEADING AND MUST ATTEND BIOPHARMA EVENT WITH QUALITY CONTENT & EXCELLENT PLATFORM TO NETWORK WITH LEADERS OF THE INDUSTRY
BDP CHINA 2018 STRONG VALUE PROPOSITION
3
CO-LOCATED CONFERENCES WITH INTERACTIVE
SESSIONS
300+
SENIOR PHARMA ATTENDEES
60+
EXPERT SPEAKERS
60+
MARKET FACING SESSIONS
1
JOINT EXHIBITION & NETWORKING AREA
MAIN CONFERENCE DAY ONE - WEDNESDAY, 16 MAY 2018
BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS
08:00 Main Conference Registration and Morning Coffee
08:50 Welcome Address from IBC Asia
09:00 Chairperson's Opening Remarks
Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China
09:10 Global and Local Biopharma Market Trends and Implications
? Innovation in biopharma pipelines ? what can we expect ? Recent regulatory developments ? obstacle or opportunity? ? How digitalisation of BioPharma is creating new value propositions ? Biomanufacturing market snapshot in China ? Biosimilars market potential ? what can we achieve? ? New trends in cell line development Moderator: Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China
Panellists: Jerry Yang, SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China Xu Wei, Vice President, Manufacturing, Innovent Biologics, China Xiao Zhi Hua, Chief Executive Officer, OPM Biosciences, China Jun Liu, Vice President, TOT Biopharma, China Yanshan Huang, Chief Executive Officer, DOER Biologics, China
10:10 Global M&A Trends and Deal Flow in the Outsourced Pharma Manufacturing Services Sector
Andrew Huntley, Senior Managing Director, BDA Partners, UK
10:50 Morning Networking & Refreshment Break
11:20 Chairperson's Opening Remarks
Xu Wei, Vice President, Manufacturing, Innovent Biologics, China
THE MARKETING AUTHORIZATION HOLDER (MAH) REGIME
11:25
Overview of Biotech Product Manufacturing-A Regulatory Perspective
Zhihao(Peter) Qiu, Branch Chief, Division of Inspectional Assessment, Office of Process and
Facilities, Office of Pharmaceutical Quality, CDER, FDA, U.S.
11:55
Industry Panel: Striving to Achieve Nationwide Implementation of the MAH Regime- What Can we Expect?
Moderator: Xu Wei, Vice President, Manufacturing, Innovent Biologics, China Jerry Yang, SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd. China Zhihao(Peter) Qiu, Branch Chief, Division of Inspectional Assessment, Office of Process and Facilities, Office of Pharmaceutical Quality, CDER, FDA, U.S. Zack Zheng, Ph.D. VP of Process Development (Wuhan), JHL BioTech, China
CAS E STUDY
UTILITY EFFICIENCY AND OPTIMIZATION
13:30 A Case Study on Setting Up Merck's E2E Biodevelopment Center in Shanghai
Aurore Lahille, Head of EMEA E2E Process Development, Merck, France
14:00 Optimising Continuous Process with Smart Technologies
Swee Nguan Lim, Director of Asia Pacific Sales, Finesse, part of Thermo Fisher Scientific, Singapore
14:30 Case Study: Building a WorldClass Highly Flexible Continuous Manufacturing Facility and Quality System in China
Dr. Frank Ye, SVP of Manufacturing and Quality, Hangzhou Just Biotherapeutics Co., Ltd., China
CAS E STUDY
11:20 Chairperson's Opening Remarks
Sunny Zhou, Professor, Department of Chemistry and Chemical Biology, Northeastern University, USA
CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND STABILITY
11:30
Generation of Unique Clone Fingerprints for Control and Enhancement of CHO Cell Factories
Jerry Clifford, Chief Operating Officer, Valitacell, Ireland
12:00 Using Nanoscale Bioreactors To Select Top CHO Clones and Predict Stability in 5 Days
Keith Breinlinger, Chief Technology Officer, Berkeley Lights Inc.
12:30 Networking Lunch
ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES
13:40 Applications of a New All-in-One Seeding and Imaging System in the Rapid Establishment of Monoclonal Cell Lines
George Hutchinson, Head of Global Distribution, Solentim, UK
14:20 Highly Productive Cell Line Development Platform
Eric Chang, Head of Cell Line Development, JHL Biotech, Taiwan
11:10
Chairperson's Opening Remarks
Dr. Ming Wang, President and Chief Executive
Officer, Phanes Biopharmaceuticals, China
CHINA'S BIOSIMILARS MARKET
11:10 Nutritional Levers for Biosimilarity
Dr. Ryan Karcher, Senior R&D Scientist & Team
Lead, Merck, U.S
CAS E STUDY
11:40
The Importance of Media and Supplements in Two Biosimilar CHO Cell Lines
Henry Zhang, APAC Technical Application Representative, Kerry Inc., China
12:10
China Market Insight: Market Outlook
and Update on Biosmilars Pipelines
Dr. Scott Liu, President and CEO, Shanghai Henlius Biotech Inc., China
13:30 China Market Insight: Market Growth and Opportunities in Therapeutic Biosimilars
Xiao Zhi Hua, Chief Executive Officer, OPM Biosciences, China
14:00 Managing Costs and Technology Adoption in Biosimilar Development
Dr. Manfred Weiler, Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK
14:30 Biosimilars Development in China: Challenges in Bevacizumab Clinical Trial Design
Dr. Jacqueline Ming Liu, Vice President, TOT Biopharma, China
15:30
Case study: Scale-up of Continuous
Capture Chromatography
Johnson David M, Senior Global Product Manager, Continuous Purification, Pall Life Sciences, U.K.
16:00 Innovation in Chromatograpy Platform: Lattice Supported Modular Chromatography using Conventional Resin Enabling Flexible Operations, Linear Scalability & Hyper-Productive Processes
Masayoshi Nagaya, Sr. Global Technology Manager, JSR Life Sciences, US
16:30 Current Challenges of Biologics
Manufacturing in China
Xu Wei, Vice President, Manufacturing, Innovent Biologics, China
17:00 Efficacy of Insulation Systems in Aseptic areas and facilities: A Practical Guide to Facility Cost Reduction
David Sadler, President & CEO, Kunshan Zotek Kinglai Co. Ltd. U.K.
17:30
From Process Development to cGMP
Manufacturing - Process Control Strategy
Zack Zheng, Ph.D. VP of Process Development (Wuhan), JHL BioTech, China
15:00 Afternoon Networking & Refreshment Break
15:30 One Step Approach of Scale-Up in Process Development
Dr Jun Liu, Vice President, TOT Biopharma, China
QBD, PAT AND EARLY INTERVENTION STRATEGIES
16:00 Improving Late-Stage Product Quality Through Early Cell Culture Intervention
Sunny Zhou, Professor, Department of Chemistry and Chemical Biology, Northeastern University, USA
16:30 Glycans Before Lunch: Rapid N-Glycan Sample Preparation Workflows for Liquid Chromatography and Capillary Electrophoresis Platforms
Dr. John Yan, Applications Scientist, ProZyme, USA
QUALITY AND SIMILARITY ASSESSMENT
15:30 Biosimilar Clinical Materials: Changes
and Comparability
Dr Qiwei Wu, Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma, China
FIRESIDE CHAT
16:10
Fireside Chat: Analytical and Quality Assessment of Biosimilars
Interviewer:
Dr. Ming Wang, President and Chief Executive Officer, Phanes Biopharmaceuticals, China Interviewee:
Dr Amy Hong Que, Vice President ? Quality, Innovent Biologics, China
16:40 End of Day Round-up Q&A session
17:00 A Quality by Design (QbD) Approach for Early Stage Cell-Culture Process Development
Hung Fai Poon, President, Quacell Biotech, China
17:30 Glycosylation Analysis and Control for
Improved Product Quality
Julie Wei, Director, JUST Biotherapeutics, China
17:55 Chairperson's Summary and End of Main Conference Day One followed by Networking Cocktail
MAIN CONFERENCE DAY TWO - THURSDAY, 17 MAY 2018
09:00 Chairperson's Opening Remarks
Yun Kang, Vice President of Manufacturing, Generon Beijing, China
INNOVATIONS IN MANUFACTURING SCIENCE AND TECHNOLOGY
09:00 Expediting the Process from CMC Development to Multi-Region Clinical Trials
Yun Kang, Vice President of Manufacturing, Generon Beijing, China
09:20 Rapid Microbiological Methods: Current Endotoxin/Sterility/Bacterial ID Applications in Bio Pharmaceutical Operations
John Dubczak, Director of Operations, Charles River Laboratories, U.S.
09:50 Multi-column, Parallelized Unit Operations Using a Single-Skid for Intensified DSP at Pilot Scale
Nicolas-Julian Hilbold, DSP Innovation Specialist, Merck KGaA (sponsored by Novasep)
10:20 New Challenge by Samsung BioLogics in Biopharmaceutical Development and Manufacturing
Eun Young Yang, Executive Director, Head of CDO Business Development Team, Samsung BioLogics, Korea
09:00 Chairperson's Opening Remarks
Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA
EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS
9:10 Liquid Engineering: CHO Cell Culture Performance Enhancement Using Small Molecules
Prof. David James, University of Sheffield, UK
9:40
Engineering a Fully Human HEK293 System for the High Titer Production of Recombinant Glycoprotein
Ng Say Kong, Staff Scientist, Animal Cell Technology 2, Bioprocessing Technology Institute, A*STAR, Singapore
10:10
Progressing Tech-Transfer and Cell
Culture Scale-Up for Biotherapeutics
Zhiwei Pan, Senior Director of Process Development, Livzon Mabpharm, China
09:00 Chairperson's Opening Remarks
Dr. Alvin Luk, Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China
GOING GLOBAL AND PARTNERSHIPS
09:10 Opening Address: Key Learnings from a Global Perspective: How to Unlock the Full Potential of Biosimiliars ? Learnings from EU on Access and Procurement
Prof. Dr. Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany
CAS E STUDY
09:40 Case Study: Global Development Strategy on Biosimilars: How to Win in the International Space
Pearl Fong, Associate Vice President, Division of Project Development, Mycenax Biotech Inc.,Taiwan
CAS E STUDY
10:10
Biopharma's Case Study: Perspective on Biosimilars Market Development, and China Market Potential and Partnerships
Bryan Kim, Vice President of Business Development, Samsung Bioepis, Korea
10:40 Morning Networking & Refreshment Break
COLD CHAIN MANAGEMENT
11.10 Designing and Developing a Quality Driven Process to Mitigate Risk in Delivering Temperature Sensitive Biopharmaceuticals to Market
Iris Desiree Sioson, Reliability Manager, APAC, Envirotainer, Singapore
QUALITY COMPLIANCE AND SYSTEM
11:40
Strategic Practice in Building Quality Management Systems (QMS) in China Facilities
Dr. Dennis Yu Xia, Vice President of Manufacturing and Quality, Akeso Bio, China
THERAPEUTIC MAB INNOVATION AND DISCOVERY
11.10 Design Novel Polyagonist Drugs forObesity & Type II Diabetes
Shaoqing Yang, Vice President, Zhejiang Doer Biologics Co., China
NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION SYSTEMS
11.40
Fireside Chat: Manufacturing Stable Expression Platforms by Gene Engineering Technology
Interviewer: Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Inc, USA Interviewee: Wang Tong Ying, Chief Technical Officer, Hangzhou Jiuyuan Gene Engineering, China
SAFETY AND EFFICACY
11:10
A Biopharma Solution for Automated
Glycan Characterization
Dr. Sven Bahrke, Senior Director Cooperations, Glycotope GmBH, Germany
11:40
The Long and Winding Road: Operational
Challenges for Biosimilar Clinical Trials
Dr Xin Zhang, Vice President of Global Clinical Operations and Affairs, Shanghai Henlius Biotech, Inc., China
12:10 Networking Lunch
13:10
The Practice and Challenge of MAH Pilot Program under Current CFDA Regulation
Dr. Jiali Luo, General Manager, Boehringer Ingelheim Biopharmaceuticals, China
FACILITIES AS COMPETITIVE ADVANTAGE
CAS E STUDY
13:50
Case Study: Building a WHO PQ
Compliant New Facility
Dr. John Zeng, Executive Vice President, Bioprocess Development & Pilot Plant Manufacturing Shanghai Zerun Biotech Co Ltd, China
14:30 GMP Biomanufacturing Facility Design and Operation ? Cultural Clash Between East and West
Dr. Jinyou Zhang, Senior Vice President/Head, Bio Development and Manufacturing, BeiGene Co. Ltd., China
15:10
Microbial Control During Biologics
Manufacturing
Hui Cai, Head of QC Laboratory 2 & Head of Microbial Control Team, WuXi Biologics, China
13:10
Panel Discussion: Next Generation Non-CHO Expression Systems for Novel Biotherapeutic Applications
Moderator: Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA Panellists: Dong Huifang, Director of Cell Line Development, WuXi Biologics, China Dr Jun Yuan, R&D Director, Quacell Biotech, China Sai Ling Liu, Product Development Expert, Surfer Biotech, China
14:00 Aiming for High Productivity and Stability in the Era of CHO Genome
Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D,
Pfizer Inc, USA
14:40 Challenges & Opportunities of
Biotherapeutic Glcosylation
Zhou Hui, Chief Executive Officer, Glycogene Biotherapeutics, China
15:10
Rapid Protein Production in CHO Cells:
From Transfection to 100 g in 6 Weeks
Dong Huifang, Director of Cell Line Development, WuXi Biologics, China
COMMERCIALISATION OF BIOSIMILARS
CAS E STUDY
13:10
Biopharma's Case Study: Remsima? Success Story and Strategy to Overcome Hurdles, Move into Mainstream
MinSeob Lee, Team Leader of R&D CMC/PM, Celltrion R&D, Korea
14:00 Commercialization Practicality: CFDA's Requirement on `Biosimilar Application and RA Operation Support Model
Eric Liu, China Biosimilars Regulation Publishing Manager, Pfizer, China
14:50 Applying High Throughput Process Development Platform to Develop Downstream Process for Clinical Manufacturing
Jiang Junjun, Assistant Director, WuXi Biologics, China
15:40 Afternoon Networking and Refreshment Break
BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 CLOSING PLENARY SESSIONS
16:20
BDP China 2018 Round Up Panel: A vision for China's Biopharma Industry in the Next Decade
? Enabling drivers of innovation in China ? Consolidation of local players ? Shifting investment from manufacturing focus to innovative portfolios ? Adopting technologies that enable the potential in manufacturing, cell
development and similarity ? Attracting the right talent
Moderator: Yun Kang, Vice President of Manufacturing, Generon Beijing, China Panellists: Zheru Zhang, President, I-Mab Biopharma, China Dr. Alvin Luk, Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China Shaoqing Yang, Vice President, Zhejiang Doer Biologics Co., China
17:00 Chairperson's Summary of the Day and End of Conference
Session outline may change to accomodate market-specific or company development.
PRE-CONFERENCE WORKSHOPS TUESDAY 15 MAY 2018
9.00AM - 4.40PM
PALL CONTINUOUS BIOPROCESSING WORKSHOP
Daniel Ming Yuan, Biotech Business Unit
GM, Pall China
Jun Wang, Ph.D., Marketing Manager, Biotech BU, Pall China
Schofield Mark., Senior Manager, R&D
Workshop Leaders:
Johnson David M., Senior Global Product Manager, Continuous
Purification
Peter Shen, VP, Process Development & Clinical Manufacturing, WuXi
Biologics, Inc
Meng Yang, Senior Technical Manager, Biotech BU, Pall China
Tao Shi, Senior SLS Manager, Biotech BU,
Pall China
AGENDA AT A GLANCE:
9.00AM - 1.00PM 1. INTEGRATED PROCESS DEVELOPMENT AND PROTEIN ANALYTICS TO IMPROVE BIOSIMILARITY
Yunfen He, Senior Director, OPM Biosciences
2. QUALITY CONTROL & CHARACTERIZATION IN ANTIBODY DRUGS DEVELOPMENT
Zhigui Zhou, Director, OPM Biosciences
3. KEY CONSIDERATIONS IN PK OF BIOSIMILAR DEVELOPMENT
Lihou Dong, Senior Director, United-Power Pharma
EXPLORE MAH REGIME FOR BOTH PHARMA AND CMOS IN CHINA
DISCOVER APPLICATION OF NEW DISRUPTIVE TECHNOLOGIES AND
IMPROVEMENT ON PROCESS DEVELOPMENT
GLOBAL TRENDS IN FACILITIES OF THE FUTURE
SINGLE USE SYSTEMS
NEW CASE STUDIES ON ACHIEVING OPERATIONAL, QUALITY AND COST
EFFECTIVENESS
COMPLIANCE IMPROVEMENTS AND HOW TO GET CLOSER TO FDA
EXPECTATIONS
CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND
STABILITY
ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES
OVERVIEW OF THE GLOBAL BIOSIMILARS MARKET AND OUTLOOK
EXPLORE GLOBAL MARKET POTENTIAL AND PARTNERSHIPS
STRATEGY
QBD, PAT AND EARLY INTERVENTION STRATEGIES
EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS
THERAPEUTIC MAB INNOVATION AND DISCOVERY
NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION
SYSTEMS
PROCESS, RESTRICTIONS AND GUIDELINES TO GAIN REGULATORY
APPROVAL
ASSESS QUALITY AND SIMILARITY OF BIOSIMILARS
SAFETY, EFFICACY AND RISK CONSIDERATION
COMMERCIALIZATION OF BIOSIMILARS ? CHALLENGES AND
OPPORTUNITIES
"IT'S A WONDERFUL MEETING AND I OBTAINED MUCH MORE KNOWLEDGE AND I RECOMMEND IT NEXT YEAR"
Senior Medical Manager, Shanghai Hengrui Pharmaceutical Co., Ltd
Media Partners:
Supporting Association:
The Biopharma Development & Production Week hosts China's key biopharma leaders and international experts, prides itself as a leading industry platform for its practical contents, quality of sessions, excellent networking platform and THE gathering place for pharma, biotech, CMOs, CROs, research institutes, investors, technology and industry stakeholders.
WHO SHOULD ATTEND:
? Chief Executive Officer
? Chief Operations Officer
? Chief Scientific Officer
? Chief Technology Officer
? Business Development and Marketing
? Head of Analytics
? Head of Cell Line Development
? Head of Manufacturing, Bioprocessing, Operations
? Head of Process Sciences and Manufacturing
? Head of Quality Assurance & Quality Control
? Principal Scientist
? USP & DSP Specialists
? VPs & Directors of Biosimilars
? VPs & Directors of Process Development
? VPs & Directors of R&D
MEET YOUR TARGET AUDIENCE: BY COUNTRY:
60% China
15%
Other Asian Countires
10% US
5%
Other Regions
10% Europe
BY INUSTRY:
Pharma/Biopharma/Biotech....................................... 55% CMO/CRO...............................................................................10% Government Agencies..........................................................2% Laboratory Equipment & Technology.......................... 4% Industry & Laboratory Chemicals....................................3% Pharma Construction & Engineering Services.......... 1% Cold Chain Supplies............................................................. 4% Academics/Research Institutes/Consultancy........... 1% Other Service Providers.................................................... 20%
WHAT PAST ATTENDEES SAID:
"GREAT EVENT WITH LOTS OF INSIGHTS ON CHINESE MARKET AND DEVELOPERS. MET MANY GREAT PEOPLE."
Tucker Herbert, Manager, ZS Associates
"WELL ORGANIZED, EXPANDING THE VISION OF THE BIO INDUSTRY IN DIFFERENT COUNTRIES IN ASIA."
Jinhua Zhang, Business Development Director, Livzon MabPharm
"IT'S QUITE MORE PROFESSIONAL THAN NORMAL COMMERCIAL CONFERENCE."
Yunxia Xu,PM,Centergene
SPONSORS AND EXHIBITORS:
GOLD SPONSORS:
BRONZE SPONSORS:
ASSOCIATE SPONSOR:
SESSION SPOTLIGHT SPONSORS: EXHIBITORS:
EXHIBITION FLOORPLAN:
Host Lucky Draws During the
Networking Breaks
WIFI Sponsor
Area
10 9 8
1
7
Exclusive Sitting Lunch Room Available for Sponsorship
Buffet 14
13
15 16 17 18
12 3
19 20
37
11 2
36
38
35
39
34
40
41
27 28
33 32
6
26
29
25
30
24 23
31
5
22
Exclusive Sponsor Meeting Rooms Available Upon Request 21
Entrance
8
4
9
=VIP
INTERACTIVE COMMON AREA FOR
EXHIBITION AND REFRESHMENT BREAKS
SPONSORSHIP OPPORTUNITIES
Sponsorship opportunities are now also available. To position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available, please contact: Ms. Yvonne Leong at Tel: +65 6508 2489 l Email: Yvonne.Leong@.sg
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- syneos health rare disease consortium
- rare disease day symposium
- 8 triangle business journal space 4q 2017 2018 space
- raleigh durham office q4 2018 vacancy declines despite
- 中国 生物制药研发和产品周 s3 ap southeast 1
- mbbs drcog ffpm
- naics code company name employees address city zip phone
- 2018 nho company overview slides edu
Related searches
- ap physics 1 practice exam
- ap physics 1 kinematic problems
- ap physics 1 2019 answers
- ap physics 1 free response questions
- ap physics 1 2015 frq
- ap physics 1 released frq
- ap physics 1 2014 frq
- ap physics 1 exam 2020
- ap physics 1 2020 frq
- ap physics 1 syllabus 2020
- ap physics 1 workbook
- ap physics 1 workbook 2019